Two Sigma Securities’s Celldex Therapeutics CLDX Stock Holding History

Two Sigma Securities’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-806	Closed	-$5K	–	2228
2018 Q3	$5K	Buy	+806	New	+$5.64K	﹤0.01%	2512

Other funds holding CLDX

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

KLP Enterprises Branford, Connecticut $1.97M AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Securities's CLDX Position: Q4 2018 in Review

Two Sigma Securities sold out of Celldex Therapeutics (CLDX) in Q4 2018, closing a stake of 806 shares — an estimated $5K sold.

Two Sigma Securities first reported a position in CLDX in Q3 2018 and held it in 1 quarter. The position peaked at $5K in Q3 2018. 85 funds tracked by Wall St. Rank hold CLDX as of Q4 2018.

Two Sigma Securities reported no remaining Celldex Therapeutics position as of Q4 2018 after selling out during the quarter.
Two Sigma Securities sold 806 Celldex Therapeutics shares in Q4 2018, an estimated $5K.
Two Sigma Securities first reported a position in Celldex Therapeutics in Q3 2018 and held it in 1 quarter.
Two Sigma Securities's Celldex Therapeutics position peaked at $5K in Q3 2018.
85 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2018.

Based on Two Sigma Securities's 13F filing for Q4 2018, filed 14 Feb 2019.